- Home
- PSNY vs AUPH Comparison
PSNY vs AUPH Comparison
Compare PSNY & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNY | AUPH |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | Sweden | Canada |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PSNY | AUPH |
|---|---|---|
| Price | $17.04 | $14.28 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $15.00 | ★ $17.25 |
| AVG Volume (30 Days) | 175.6K | ★ 1.1M |
| Earning Date | 03-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $49.59 | $16.53 |
| Revenue Next Year | $31.71 | $16.24 |
| P/E Ratio | ★ N/A | $7.06 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $0.50 | $6.83 |
| 52 Week High | $23.28 | $16.54 |
Technical Indicators
Market Signals| Indicator | PSNY | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 48.71 |
| Support Level | $15.55 | $13.52 |
| Resistance Level | $19.00 | $15.23 |
| Average True Range (ATR) | 0.95 | 0.46 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 48.75 | 33.82 |
Price Performance
Historical ComparisonAbout PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.